Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol Receives U.S. Orphan Drug Designation for SM101
Martinsried/Munich, Germany, April 19, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that the FDA's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) for SuppreMol's lead product SM101, a recombinant human...

---

SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101
Martinsried/Munich, Germany, April 12, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the initiation of a Phase Ib/IIa clinical trial with its lead product SM101 in Idiopathic Thrombocytopenic Purpura (ITP). The first patient in the...

---

SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing
Martinsried/Munich, Germany, February 8, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing. Most recently, Dr. Phelps has been Director Business...

---

SuppreMol receives public research funding for its lead project SM101
Martinsried/Munich, Germany, September 7, 2009 -- SuppreMol GmbH, a privatelyheld biopharmaceutical company developing novel therapeutics for the treatment ofautoimmune diseases, today announced it has been awarded research funding from the federal program "KMU-Innovativ" by the German Federal Ministry of Educationand Research (BMBF)....

---

Uwe Jacob resigned today from his position as Corporate Development Officer at SuppreMol.
Dr. Uwe Jacob is leaving SuppreMol Uwe Jacob resigned today from his position as Corporate Development Officer at SuppreMol. Uwe will pursue other activities outside of SuppreMol but he will continue working for the Company as a consultant in specific projects as well as a member of the Scientific Advisory Board. Uwe Jacob is one of the three...

---